Literature DB >> 19111508

The application of toxins and venoms to cardiovascular drug discovery.

Wayne C Hodgson1, Geoffrey K Isbister.   

Abstract

Animal venoms contain a variety of highly selective and potent toxins, which have evolved over thousands/millions of years, which target vital physiological processes. As such, they have proven to be an excellent source of lead compounds for the development of therapeutic agents. In particular, a number of these venom components (e.g. bradykinin-potentiating peptides, sarafotoxins, natriuretic peptides) have profound effects on the cardiovascular system. This review article examines recent progress in the search for lead compounds or novel scaffolds for cardiovascular drug development from animal venoms.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19111508     DOI: 10.1016/j.coph.2008.11.007

Source DB:  PubMed          Journal:  Curr Opin Pharmacol        ISSN: 1471-4892            Impact factor:   5.547


  6 in total

1.  D. russelii Venom Mediates Vasodilatation of Resistance Like Arteries via Activation of Kv and KCa Channels.

Authors:  Rahini Kakumanu; Sanjaya Kuruppu; Lachlan D Rash; Geoffrey K Isbister; Wayne C Hodgson; Barbara K Kemp-Harper
Journal:  Toxins (Basel)       Date:  2019-04-01       Impact factor: 4.546

2.  Profiling the resting venom gland of the scorpion Tityus stigmurus through a transcriptomic survey.

Authors:  Diego D Almeida; Katia C Scortecci; Leonardo S Kobashi; Lucymara F Agnez-Lima; Silvia R B Medeiros; Arnóbio A Silva-Junior; Inácio de L M Junqueira-de-Azevedo; Matheus de F Fernandes-Pedrosa
Journal:  BMC Genomics       Date:  2012-08-01       Impact factor: 3.969

3.  Scorpion peptides: potential use for new drug development.

Authors:  Bennasr Hmed; Hammami Turky Serria; Zeghal Khaled Mounir
Journal:  J Toxicol       Date:  2013-06-15

4.  Elapid snake venom analyses show the specificity of the peptide composition at the level of genera Naja and Notechis.

Authors:  Aisha Munawar; Maria Trusch; Dessislava Georgieva; Diana Hildebrand; Marcel Kwiatkowski; Henning Behnken; Sönke Harder; Raghuvir Arni; Patrick Spencer; Hartmut Schlüter; Christian Betzel
Journal:  Toxins (Basel)       Date:  2014-02-28       Impact factor: 4.546

5.  Correlation between the glycan variations and defibrinogenating activities of acutobin and its recombinant glycoforms.

Authors:  Ying-Ming Wang; Inn-Ho Tsai; Jin-Mei Chen; An-Chun Cheng; Kay-Hooi Khoo
Journal:  PLoS One       Date:  2014-06-19       Impact factor: 3.240

6.  An in vivo examination of the differences between rapid cardiovascular collapse and prolonged hypotension induced by snake venom.

Authors:  Rahini Kakumanu; Barbara K Kemp-Harper; Anjana Silva; Sanjaya Kuruppu; Geoffrey K Isbister; Wayne C Hodgson
Journal:  Sci Rep       Date:  2019-12-27       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.